Full Event Guide

b3dd brochure

Over 3 days, key speakers from the CNS industry will share their work with the B3DD community to address the translational challenges of delivering candidates to
the CNS:

Protein Engineering of FC5 for Enhanced & Sustained CNS Exposure of Neuro-therapeutic Antibodies - Thomas Cameron, Associate Director, Biologics Drug Discovery, Biogen

Clinical Efficacy of Antibody-enzyme Fusion Proteins as Carrier Platform to Transport Lysosomal Enzymes Across the BBB for the Treatment of Mucopolysaccharidosis Type I - Mathias Schmidt, Chief Executive Officer, ArmaGen

Assessing Microphysiological Models of the BBB - Graham Marsh, Scientist I, Translational Biology, Biogen

Employing in vivo Microdialysis & Microperfusion Methods to Understand Brain Disposition of Biologics for the Treatment of CNS Disorders - Mario Mezler, Principle Scientist, AbbVie